Cutler Group’s CorMedix CRMD Stock Holding History

Cutler Group’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-660	Closed	-$26K	–	6478
2016 Q4	$26K	Hold	660	–	–	﹤0.01%	3181
2016 Q3	$23K	Hold	660	–	–	﹤0.01%	3270
2016 Q2	$24K	Sell	660 -700	-51%	-$10.7K	﹤0.01%	3146
2016 Q1	$29K	Sell	1,360 -60	-4%	-$582	﹤0.01%	2870
2015 Q4	$30K	Buy	+1,420	New	+$16.3K	﹤0.01%	2982

Other funds holding CRMD

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Cutler Group's CRMD Position: Q4 2017 in Review

Cutler Group sold out of CorMedix (CRMD) in Q4 2017, closing a stake of 240 shares.

Cutler Group first reported a position in CRMD in Q4 2015 and held it in 8 quarters. The position peaked at $18K in Q1 2016. 34 funds tracked by Wall St. Rank hold CRMD as of Q4 2017.

Cutler Group reported no remaining CorMedix position as of Q4 2017 after selling out during the quarter.
Cutler Group sold 240 CorMedix shares in Q4 2017.
Cutler Group first reported a position in CorMedix in Q4 2015 and held it in 8 quarters.
Cutler Group's CorMedix position peaked at $18K in Q1 2016.
34 funds tracked by Wall St. Rank held CorMedix as of Q4 2017.

Based on Cutler Group's 13F filing for Q4 2017, filed 17 Jan 2018.